Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 Next >
Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science at ESMO Congress 2022
From Bayer
Via Business Wire
Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian
From Bayer
Via Business Wire
Food Security Top Concern for Majority of Americans
From Bayer
Via Business Wire
Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian
From Bayer
Via Business Wire
FDA Label Update Reflects Bayer’s Commitment to Providing Options for Long-acting Contraception
From Bayer
Via Business Wire
Bayer Launches ForGround, a Unique Sustainable Agriculture Platform Focused on Transforming How Farmers and Companies Collaborate
From Bayer
Via Business Wire
U.S. FDA Approves Additional Indication of NUBEQA® (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
From Bayer
Via Business Wire
Stem & Root Daily Immunity Named Immune Support “Product of the Year” at NutraIngredients-USA Annual Industry Awards
From Bayer
Via Business Wire
Bayer Earns Top Score on 2022 Disability Equality Index
From Bayer
Via Business Wire
Astepro® Allergy, First and Only Steroid-Free Antihistamine Nasal Spray Now Available Over-the-Counter
From Bayer
Via Business Wire
Bayer Opens New Research & Innovation Center in Boston-Cambridge Demonstrating Its Commitment to Precision Oncology
From Bayer
Via Business Wire
Bayer’s KERENDIA® (finerenone) Receives New Recommendations From American Diabetes Association for Improving Cardiovascular Outcomes and Managing Patients With Chronic Kidney Disease Associated With Type 2 Diabetes
From Bayer
Via Business Wire
Alka-Seltzer® Launches New Hangover Relief Product in a Musical Collaboration with T-Pain
From Bayer
Via Business Wire
Bayer Launches Calantic™ Digital Solutions to help Address Radiology Industry Challenges
From Bayer
Via Business Wire
Midol® Encourages Menstruators to Find Comfort in Speaking Up and Acknowledging ‘The Real Reason’ Behind Changing Plans When Period Symptoms Strike
From Bayer
Via Business Wire
Bayer and Luke Bryan Continue Partnership to Celebrate America’s Farmers and Fight Hunger with #HeresToTheFarmer Campaign
From Bayer
Via Business Wire
Bayer’s Vividion Emerging as Significant Player in San Diego Biotech Hub
From Bayer
Via Business Wire
Bayer Appoints Two New Members to U.S. Country Leadership Team
From Bayer
Via Business Wire
Bayer to Present Key Data Across Oncology Portfolio Showcasing Significant Advances in Cancer Care at 2022 ASCO Annual Meeting
From Bayer
Via Business Wire
U.S. FDA Accepts Supplemental New Drug Application (sNDA) and Grants Priority Review for NUBEQA® (darolutamide) in Combination with Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
From Bayer
Via Business Wire
Claritin® Teams Up with Nate Berkus and Jeremiah Brent to Inspire Families to Spend More Time Outside and Embrace their Outdoor Space
From Bayer
Via Business Wire
Bayer to Create Ag Biologicals Powerhouse Partnership with Ginkgo Bioworks, Advancing Joyn Bio Technology Platforms
From Bayer
Via Business Wire
Bayer Presents New Subgroup Analyses for KERENDIA® (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without History of Atherosclerotic Cardiovascular Disease
From Bayer
Via Business Wire
Bayer Set to Drive Breakthrough Innovations in the Life Sciences
From Bayer
Via Business Wire
Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program
From Bayer
Via Business Wire
Stem and Root and Nutrileads Announce Launch of Daily Immunity for Optimized Immune Function Powered by BeniCaros for Ground Breaking Immunity Support
From Bayer
Via Business Wire
Positive Results from Phase III Investigational Trial Shows NUBEQA® (darolutamide) Plus Androgen Deprivation Therapy (ADT) and Docetaxel Significantly Increases Overall Survival (OS) in Patients with mHSPC
From Bayer
Via Business Wire
Bayer Highlights Advancements of Agriculture Industry’s Most Prolific R&D Pipeline
From Bayer
Via Business Wire
Bayer Receives FDA Fast Track Designation for asundexian Stroke Program
From Bayer
Via Business Wire
Bayer Earns Top Score in 2022 Corporate Equality Index for Fifth Consecutive Year
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.